Fosamax Osteonecrosis of the Jaw Attorney: California Fosamax Osteonecrosis of the Jaw Injury Lawyer

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Individual Risk Consideration

General health and science communication has long served as a foundation for public understanding of medical conditions and treatment options. Within this legacy framework, audiences have been educated about the benefits and risks associated with various pharmaceutical interventions, including those for bone density management. This broad informational context has historically emphasized patient awareness and informed decision-making in clinical settings. As this general health discourse evolves, a natural progression emerges toward examining specific exposure scenarios that may arise from routine medical care. The transition from population-level health guidance to individual risk consideration becomes particularly relevant when addressing long-term medication use and its potential consequences. In this continuum, the focus shifts from general therapeutic benefits to the practical realities faced by patients who have undergone sustained treatment regimens. This pivot leads directly to occupational and environmental exposure considerations, where the same pharmaceutical compounds that offer therapeutic value may present distinct challenges in certain contexts. For individuals who have been prescribed medications for bone health over extended periods, the question of exposure duration and cumulative effect becomes paramount. The transition from general health information to specific exposure concern is thus a logical extension of the legacy framework, allowing for a more targeted examination of how prolonged pharmaceutical exposure might intersect with individual health outcomes in real-world settings.

Fosamax and Osteonecrosis of the Jaw: An Overview

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). While effective at reducing fracture risk, its use has been associated with a rare but serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, often occurring spontaneously but generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section reviews the clinical presentation, pharmacological mechanisms, risk factors, and legal considerations for affected patients, based on available evidence.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw presents as exposed bone in the maxillofacial region that persists for more than eight weeks in the absence of prior radiation therapy. Patients may experience pain, swelling, infection, and difficulty with chewing or speaking. Diagnosis is primarily clinical, supported by imaging such as panoramic radiographs or CT scans. The condition can occur spontaneously, but it is frequently triggered by invasive dental procedures, including tooth extraction, dental implants, or boney surgery (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax varies widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Fosamax Pharmacology and Mechanistic Pathways to ONJ

Fosamax is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. This mechanism is beneficial for increasing bone mass and reducing fractures in osteoporosis, but it also suppresses normal bone turnover. The jawbone has unique characteristics, including high remodeling rates and constant mechanical stress from chewing. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The suppression of osteoclast activity in the jaw may impair the healing of microdamage and increase susceptibility to infection, particularly after dental procedures. Additionally, bisphosphonates accumulate in bone and can be released over years, potentially prolonging the risk. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Risk Factors and Timeline of Harm

Known risk factors for ONJ include invasive dental procedures, diagnosis of cancer, concomitant therapies such as chemotherapy, corticosteroids, or angiogenesis inhibitors, poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The incidence of ONJ is rare; in a study of bisphosphonate use, the incidence of atypical femoral fracture or osteonecrosis of the jaw was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). The timeline between exposure and documented harm can vary. Symptoms may appear as early as one day after starting the drug or after several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping Fosamax, but a subset experienced recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of Fosamax use has not been determined; for patients at low risk for fracture, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Adequacy of Warnings and Legal Considerations

The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The warning also lists known risk factors and advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, some patients and attorneys may question whether these warnings are adequate, particularly regarding the timing of onset and the potential for recurrence. For affected patients in California, consulting with an attorney experienced in pharmaceutical injury cases may be relevant. Legal considerations include whether the manufacturer provided sufficient information to healthcare providers and patients about the risk of ONJ, especially given that the condition can occur spontaneously and may be misattributed to other causes. Patients who have developed ONJ after using Fosamax may seek compensation for medical expenses, pain and suffering, and lost wages. An attorney can help evaluate the specific circumstances, including the duration of Fosamax use, the presence of known risk factors, and the timeline between exposure and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a rare but serious condition characterized by exposed, non-healing bone in the jaw. It has been associated with bisphosphonate medications like Fosamax (alendronate). ONJ often occurs spontaneously or after dental procedures such as tooth extraction, and may present with pain, swelling, and infection. The risk may increase with longer duration of Fosamax use.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures. The risk may also increase with longer exposure to bisphosphonates.

How soon after starting Fosamax can ONJ develop?

The time to onset of ONJ symptoms after starting Fosamax varies widely, from as early as one day to several months. Most patients experience relief after stopping the drug, but a subset may have recurrence upon rechallenge with the same or another bisphosphonate.

Are there adequate warnings about ONJ in Fosamax prescribing information?

The prescribing information for Fosamax includes a warning about ONJ, listing known risk factors and advising that discontinuation may reduce risk for patients requiring invasive dental procedures. However, some patients and attorneys question whether these warnings are sufficient, particularly regarding timing and recurrence. Legal consultation may help evaluate the adequacy of warnings in individual cases.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.